Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
7.27
-0.06 (-0.82%)
Sep 14, 2026, 9:47 AM EDT - Market open
Company Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty.
The company was incorporated in 2014 and is headquartered in Miami, Florida.
Longeveron Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Feb 12, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Stephen Willard |
Contact Details
Address: Life Science & Technology Park, Suite 520 Miami, Florida 33136 United States | |
| Phone | 844 470 2550 |
| Website | longeveron.com |
Stock Details
| Ticker Symbol | LGVN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 1721484 |
| CUSIP Number | 54303L302 |
| ISIN Number | US54303L3024 |
| Employer ID | 47-2174146 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen H. Willard Esq. | Chief Executive Officer and Director |
| Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer and Executive Chairman |
| Paul T. Lehr J.D. | General Counsel and Secretary |
| Nirav Suresh Jhaveri C.F.A., M.B.A. | Chief Financial Officer and Principal Financial and Accounting Officer |
| Devin Blass | Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing and Controls |
| Dr. Nataliya Agafonova M.D. | Chief Medical Officer |
| Lisa McClain-Moss | Vice President of Manufacturing |
| Marie Washburn | Vice President and Corporate Controller |
| Brian G Rash Ph.D. | Vice President of Research and Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 10, 2026 | SCHEDULE 13G | Filing |
| Aug 24, 2026 | 8-K | Current Report |
| Aug 19, 2026 | 8-K | Current Report |
| Aug 13, 2026 | SCHEDULE 13G/A | Filing |
| Aug 12, 2026 | 8-K | Current Report |
| Aug 12, 2026 | 10-Q | Quarterly Report |
| Aug 10, 2026 | SCHEDULE 13G | Filing |
| Jul 29, 2026 | 8-K | Current Report |
| Jul 14, 2026 | 8-K | Current Report |
| Jul 10, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |